Biotron's decision to trial Bit225 with Dolutregravir, (ViiV's...

Biotron's decision to trial Bit225 with Dolutregravir, (ViiV's Tivicay), is interesting for several reasons.

Firstly, it is one of the few HIV/AIDS treatments that can be taken orally on a daily basis.

Secondly, it is also used as a 'post exposure prophylaxis'.

And finally,

"ViiV’s Tivicay is to become available in Europe in a new dispersible tablet form to treat children living with HIV. The joint venture, majority-owned by GlaxoSmithKline with Pfizer and Shionogi as shareholders...

"https://pharmaphorum.com/news/tivicay-approved-in-europe-in-new-dispersible-tablet-for-children-with-HIV/ (January 14, 2021)